Ketamine Troches vs. RDT Wafers: Understanding the Differences

Two Formats That Look Similar but Aren't Identical

When patients receive their compounded ketamine prescription, it may be filled as a troche (a lozenge designed for slow dissolution) or as a rapidly dissolving tablet (RDT) — sometimes also called a wafer, orally disintegrating tablet (ODT), or sublingual tablet. To the patient, both may look like small tablets. But they differ meaningfully in formulation, dissolution behavior, intended absorption site, and how they should be used.

Understanding these differences helps patients use their medication correctly and communicate clearly with their provider and pharmacy. For a broader overview, see our article on what a ketamine troche is and how troches are compounded.

What Is a Troche?

A troche (also called a lozenge or pastille) is designed for slow, sustained dissolution over 10 to 20 minutes. The solid base — typically polyethylene glycol or a similar matrix — releases the active ingredient gradually as it softens and dissolves in the mouth's moisture and warmth.

Troches are designed to:

• Maintain prolonged contact with mucosal surfaces
• Release drug slowly, allowing for extended absorption
• Provide a sustained therapeutic window rather than a rapid bolus

The PEG base does not dissolve instantaneously — it softens and melts over time, which is why troches require 10 to 20 minutes of patient stillness and position maintenance.

What Is an RDT or Wafer?

A rapidly dissolving tablet (RDT) or wafer is designed for fast, near-instantaneous dissolution upon contact with saliva — typically within 30 to 60 seconds. The tablet base is typically composed of rapidly solubilizing excipients such as mannitol, sorbitol, microcrystalline cellulose, or freeze-dried (lyophilized) matrices.

RDTs are used across pharmacy for:

• Pediatric medications (children who can't swallow pills)
• Medications where fast dissolution improves convenience
• Oral drugs that benefit from rapid mucosal contact before swallowing

When applied to ketamine, an RDT dissolves rapidly but the absorption kinetics depend on how the dissolved drug is handled — if swallowed with saliva immediately, absorption occurs primarily through the GI tract (lower bioavailability); if held in contact with oral mucosa, absorption occurs sublingually.

Key Formulation Differences

Base Material

Drug Release Profile

A troche releases ketamine progressively over its dissolution period, creating a sustained drug-contact opportunity with mucosal surfaces. An RDT releases ketamine almost immediately, creating a drug-rich saliva solution within seconds. Whether that drug absorbs sublingually or is swallowed depends on how the patient manages the dissolved material.

Absorption Differences

Troche Absorption

The troche's slow dissolution ensures that a drug-rich solution is in contact with sublingual or buccal mucosa for an extended period (the full 10 to 20 minute dissolution time). This maximizes the opportunity for mucosal absorption. The gradual nature of the process may also favor transcellular transport mechanisms by maintaining steady-state drug concentration at the mucosal surface.

Expected sublingual bioavailability from troches: approximately 20 to 30 percent.

RDT Absorption

Because an RDT dissolves almost instantly, the absorbed fraction depends critically on what happens in the first few seconds:

• If the patient holds the dissolved solution in the sublingual space without swallowing, mucosal absorption can occur
• If saliva is swallowed promptly, the drug goes to the stomach and is absorbed enterally (with first-pass metabolism)

In practice, RDTs compounded for ketamine are typically intended to be held in the mouth rather than swallowed immediately. Some providers specifically instruct patients to hold the dissolved RDT in the sublingual space for 1 to 5 minutes before (or instead of) swallowing.

Expected bioavailability from ketamine RDTs depends heavily on patient technique. Studies suggest bioavailability ranges from similar to troches (~20 to 30%) with careful technique, to as low as oral bioavailability (~16 to 20%) if mostly swallowed.

Practical Handling Differences

Fragility

RDTs are significantly more fragile than troches. They can break, crumble, or dissolve from finger moisture during handling. Patients must:

• Handle RDTs carefully, removing from packaging directly onto the tongue or into position without excessive finger contact
• Protect from humidity (even touching with damp fingers can begin dissolution)
• Store in sealed packaging until the moment of use

Troches are more robust and can be handled more normally during placement.

Technique Requirements

• Troche: Place under tongue or in buccal space; hold for 10 to 20 minutes while troche dissolves; manage saliva; stay still.
• RDT: Place under tongue; the wafer dissolves within seconds; then hold the dissolved solution against the sublingual mucosa without swallowing for the provider-specified duration (often 2 to 5 minutes).

The RDT technique may feel less cumbersome to some patients because there's no solid object to manage over an extended period. However, the saliva management challenge is similar: resist swallowing the dissolved drug for the specified hold time.

Which Does Your Provider Prescribe?

The choice between troches and RDTs is typically made by the prescriber or pharmacy based on:

• Provider preference: Some providers have strong preferences based on their clinical experience with patient outcomes.
• Pharmacy capability: Not all compounding pharmacies offer both formats; some specialize in one or the other.
• Patient factors: Patients with dry mouth (xerostomia) may find troches dissolve poorly, making RDTs preferable. Patients with dexterity issues may find fragile RDTs harder to handle.
• Dose: At higher doses, the troche base volume becomes larger; very high doses may be more elegantly compounded as RDTs.

If you receive RDTs when you expected troches, or vice versa, confirm with your pharmacy that the formulation matches your provider's prescription intent. The active ingredient (ketamine HCl) and dose should be the same; only the formulation should differ.

Clinical Outcome Differences

There is no large clinical trial directly comparing ketamine troche outcomes to RDT outcomes. In practice, clinicians who work with both report comparable results when patients are appropriately instructed on technique. The key variable in both cases is how much drug actually absorbs through the mucosa versus gets swallowed — and that depends more on patient technique than on the formulation per se.

If you're switching between formulations, discuss the technique differences with your provider. You may need to modify your approach, and your expected response may differ enough that dose or frequency adjustments are warranted.

Key Takeaways

• Troches dissolve slowly (10 to 20 min); RDT wafers dissolve rapidly (30 to 60 sec) — both aim to deliver ketamine through oral mucosa.
• Troche formulation (PEG base) provides sustained drug-mucosa contact; RDT requires patient to hold dissolved solution against mucosa.
• RDTs are more fragile and humidity-sensitive than troches.
• Bioavailability is comparable when both are used with proper technique (~20 to 30%).
• The choice between formats depends on provider preference, pharmacy capability, and patient factors like dry mouth or dexterity.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches